Results from Part-1 of ON-5001: A Multi-center, Dose Escalation and Dose Finding Phase 1 Trial of ONM-501, a Dual-Acting STING Agonist

Brad Good

Brad Good is a Circle Platinum Squarespace expert and Authorized Trainer who has built on the platform since 2008, with more than 1,900 sites to his name. He makes Language Switch, a multilingual plugin for Squarespace 7.1, and writes the guides on this site.

http://www.bradgood.net
Previous
Previous

ONM-421, a pH-responsive Polymer-Drug Conjugate Nanoparticle, Delivers MMAE to Solid Tumors and Shows Antigen-Independent Antitumor Efficacy in Mice 

Next
Next

A Phase 1 Dose-escalation and Expansion Study of an Intratumorally Administered Dual STING Agonist (ONM-501) Alone and in Combination with Cemiplimab